Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2008; 133(44): 2289-2291
DOI: 10.1055/s-0028-1091275
DOI: 10.1055/s-0028-1091275
Kommentar | Commentary
Pharmakotherapie
© Georg Thieme Verlag KG Stuttgart · New York
Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun?
Ein neues Bewertungssystem: fit for the aged (FORTA)Drug therapy in the elderly: too much or too little, what to do?A new assessment system: fit for the aged (FORTA)Further Information
Publication History
eingereicht: 13.5.2008
akzeptiert: m21.8.2008
Publication Date:
22 October 2008 (online)
Schlüsselwörter
ältere Patienten - Polypharmazie - Multimorbidität - Positivbewertung
Key words
elderly patients - polypharmacy - multimorbidity - positive evaluation
Literatur
- 1 Beckett N S, Peters R, Fletcher A E. et al . Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358 1887-1898
- 2 Beers M H. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med. 1997; 157 1531-1536
- 3 Black D M, Brand R J, Greenlick M, Hughes G, Smith J. Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. J Gerontol. 1987; 42 552-557
- 4 Borchelt M. Potential side-effects and interactions in multiple medication in elderly patients: methodology and results of the Berlin Study of Aging. Z Gerontol Geriatr. 1995; 28 420-428
- 5 Dahlöf B, Devereux R B, Kjeldsen S E. et al . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359 (9311) 995-1003
- 6 Düsing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep. 2001; 3 488-492
- 7 Fick D M, Cooper J W, Wade W E, Waller J L, Maclean J R, Beers M H. Updating the Beers Criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003; 163 2716-2722
- 8 Field T S, Gurwitz J H, Harrold L R. et al . Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004; 52 1349-1354
- 9 Field T S, Mazor K M, Briesacher B, Debellis K R, Gurwitz J H. Adverse drug events resulting from patient errors in older adults. J Am Geriatr Soc. 2007; 55 271-276
- 10 Hasford J, Schröder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007; 63 1055-1061
- 11 Hense H W. MONICA Study: Epidemiology of arterial hypertension and implications for its prevention. 10-yeart results of the MONICA Study Augsburg. Dtsch Med Wochenschr. 2000; 125 1397-1402
- 12 Kaufman D W, Kelly J P, Rosenberg L, Anderson T E, Mitchell A A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002; 287 337-344
- 13 Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279 1200-1205
- 14 Lin H Y, Liao C C, Cheng S H, Wang P C, Hsueh Y S. Association of potentially inappropriate medication use with adverse outcomes in ambulatory elderly patients with chronic diseases: experience in a Taiwanese medical setting. Drugs Aging. 2008; 25 49-59
- 15 Linden M, Bär T, Helmchen H. Prevalence and appropriateness of psychotropic drug use in old age: results from the Berlin Aging Study (BASE). Int Psychogeriatr. 2004; 16 461-480
- 16 Page 2nd R L, Ruscin J M. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother. 2006; 4 297-305
- 17 Pugh M J, Hanlon J T, Zeber J E, Bierman A, Cornell J, Berlowitz D R. Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure. J Manag Care Pharm. 2006; 12 537-545
- 18 Pugh M J, Rosen A K, Montez-Rath M. et al . Potentially inappropriate prescribing for the elderly: effects of geriatric care at the patient and health care system level. Med Care. 2008; 46 167-173
- 19 Robine J M, Michel J P. Looking forward to a general theory on population aging. J Gerontol A Biol Sci Med Sci. 2004; 59 M590-597
- 20 Schnurrer J U, Frölich J C. Zur Häufigkeit und Vermeidbarkeit von tödlichen unerwünschten Arzneimittelwirkungen. Internist (Berl). 2003; 44 889-895
- 21 Schönhöfer P S. Klinik-basierte Erfassung Arzneimittel-bedingter Erkrankungen im Pharmakovigilanz-System (ZKH Bremen). Arzneimitteltherapie. 1999; 17 83-86
- 22 Shepherd J, Blauw G J, Murphy M B. et al . PROSPER study group.. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360 1623-1630
- 23 Staessen J A, Fagard R, Thijs L. et al . Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350 757-764
- 24 Steinman M A, Landefeld C S, Rosenthal G E, Berthental D, Sen S, Kaboli P J. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006; 54 1516-1523
- 25 Van den Akker M, Buntinx F, Metsemakers J F, Roos S, Knottnerus J A. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol. 1998; 51 367-375
- 26 Van Spall H G, Toren A, Kiss A, Fowler R A. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007; 297 1233-1240
- 27 Zhan C, Sangl J, Bierman A S. et al . Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA. 2001; 286 2823-2829
Prof. Dr. Martin Wehling
Klinische Pharmakologie Mannheim, Universität
Heidelberg
Maybachstraße 14
68169 Mannheim
Phone: ++49 621 383 9631
Fax: ++49 621 383 9632
Email: martin.wehling@medma.uni-heidelberg.de